Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantCP
Canaan Partners
Activity from announced rounds
All recorded activity
Canaan Partners is an investment firm whose company directory identifies Draig Therapeutics and Solstice Oncology.
Recorded funding activity
Draig develops neuropsychiatric medicines, while Solstice advances an engineered CTLA-4 antibody for cancer treatment. The recorded history also includes Actualyze AI’s enterprise gateway for model access, request security, budgets and routing. Named regional funds retain separate identities.
Sources
- Rounds participated in
- 8
- Confirmed lead rounds
- 0 7 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $765.5M 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in all activityActualyze AI
An enterprise gateway for AI-model access, request security, budgets and routing.
$7MSeed
Role not disclosedDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedVedana Therapeutics
Develops next-generation therapies for migraine prevention
$46MSeries A
Role not disclosedHeyMilo AI
Builds agentic recruiting platform that screens high-volume candidates via voice, video, SMS, and resume agents
$6MSeed
Role not disclosedSageOx
Builds shared context infrastructure for AI-native teams
$15MSeed
Role not disclosedHermeus
Develops high-Mach unmanned aircraft for national security missions
$350MSeries C
Role not disclosedNovee
Novee provides AI-powered penetration-testing software.
$51.5MSeries A
Role not disclosed